ScinoPharm Taiwan, Ltd. (TPE:1789)
Taiwan · Delayed Price · Currency is TWD 18.90
+0.25 (1.34%)
Aug 7, 2026, 1:30 PM CST
ScinoPharm Taiwan Ratios and Metrics
Market cap in millions TWD. Fiscal year is January - December.
Millions TWD. Fiscal year is Jan - Dec.
Total Valuation
Fiscal Year | Current | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Aug '26 Aug 6, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
| 14,945 | 13,245 | 17,436 | 20,876 | 20,124 | 19,492 | |
Market Cap Growth | 7.69% | -24.04% | -16.48% | 3.73% | 3.25% | -14.56% |
Enterprise Value | 12,319 | 11,170 | 14,136 | 17,530 | 16,527 | 16,275 |
Last Close Price | 18.90 | 16.51 | 21.30 | 25.24 | 24.03 | 22.84 |
Price Ratios
Fiscal Year | Current | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Aug '26 Aug 6, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
PE Ratio | 396.12 | 96.71 | 51.38 | 72.72 | 56.98 | 80.06 |
Forward PE | - | 44.08 | 58.80 | 102.52 | 52.60 | 30.88 |
PS Ratio | 4.87 | 4.19 | 5.12 | 6.55 | 6.17 | 7.06 |
PB Ratio | 1.43 | 1.26 | 1.66 | 2.01 | 1.93 | 1.85 |
P/TBV Ratio | 1.43 | 1.26 | 1.66 | 2.02 | 1.93 | 1.86 |
P/FCF Ratio | 25.90 | 43.48 | 37.04 | - | 37.93 | 99.76 |
P/OCF Ratio | 18.55 | 22.23 | 23.22 | 90.32 | 26.01 | 38.23 |
PEG Ratio | - | 1.06 | 1.06 | 1.06 | 1.06 | 1.06 |
EV Ratios
Fiscal Year | Current | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Aug '26 Aug 6, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
EV/Sales Ratio | 4.02 | 3.53 | 4.15 | 5.50 | 5.06 | 5.89 |
EV/EBITDA Ratio | 27.93 | 18.46 | 17.85 | 23.07 | 19.93 | 24.83 |
EV/EBIT Ratio | - | 102.57 | 44.03 | 55.74 | 40.76 | 56.39 |
EV/FCF Ratio | 21.35 | 36.67 | 30.03 | - | 31.15 | 83.29 |
Financial Efficiency
Fiscal Year | Current | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Aug '26 Aug 6, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Debt / Equity Ratio | 0.08 | 0.07 | 0.06 | 0.06 | 0.07 | 0.05 |
Debt / EBITDA Ratio | 1.98 | 1.22 | 0.83 | 0.80 | 0.80 | 0.83 |
Debt / FCF Ratio | 1.51 | 2.50 | 1.44 | - | 1.28 | 2.85 |
Net Debt / Equity Ratio | -0.25 | -0.22 | -0.33 | -0.32 | -0.35 | -0.33 |
Net Debt / EBITDA Ratio | -6.10 | -3.88 | -4.41 | -4.37 | -4.36 | -5.38 |
Net Debt / FCF Ratio | -4.55 | -7.71 | -7.41 | 89.04 | -6.82 | -18.04 |
Asset Turnover | 0.25 | 0.27 | 0.29 | 0.27 | 0.28 | 0.24 |
Inventory Turnover | 1.16 | 1.25 | 1.32 | 1.46 | 1.59 | 1.14 |
Quick Ratio | 3.15 | 5.26 | 6.28 | 6.52 | 6.16 | 8.04 |
Current Ratio | 4.74 | 7.74 | 8.61 | 8.75 | 7.87 | 10.73 |
Return on Equity (ROE) | 0.36% | 1.30% | 3.25% | 2.76% | 3.37% | 2.31% |
Return on Assets (ROA) | -0.35% | 0.57% | 1.70% | 1.66% | 2.15% | 1.53% |
Return on Invested Capital (ROIC) | -0.87% | 1.33% | 3.75% | 3.73% | 4.73% | 3.31% |
Return on Capital Employed (ROCE) | -0.60% | 1.00% | 2.90% | 2.90% | 3.70% | 2.60% |
Yields
Fiscal Year | Current | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Aug '26 Aug 6, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Earnings Yield | 0.25% | 1.03% | 1.95% | 1.38% | 1.75% | 1.25% |
FCF Yield | 3.86% | 2.30% | 2.70% | -0.18% | 2.64% | 1.00% |
Dividend Yield | 1.55% | 1.76% | 1.64% | 1.19% | 1.50% | 2.10% |
Payout Ratio | 733.56% | 202.09% | 69.91% | 99.17% | 107.46% | 162.39% |
Buyback Yield / Dilution | -9.21% | 0.12% | -0.07% | 0.04% | -0.05% | -0.01% |
Total Shareholder Return | -7.71% | 1.88% | 1.57% | 1.23% | 1.45% | 2.09% |